Study reveals patients’ and survivors’ perception of discussions with their healthcare team regarding options, costs, and impact on work related to prostate cancer treatment.
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.
Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
New real-world data suggest the presence of race-based differences in the therapeutic response to abiraterone.
A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
Investigators say they believe their study is the first to show a link between circulating tumor cell counts and progression-free and overall survival in men with metastatic hormone-sensitive prostate cancer.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
